Home › Research › End-of-life care
Continued Use of Cholinesterase Inhibitors and Memantine in Hospice
Lauren J. Hunt, Siqi Gan, W. John Boscardin, Krista Lyn Harrison, Matthew E. Growdon, Ulrike Muench, Lauren B. Gerlach, Alexander Kingsbury Smith et al.. JAMA Internal Medicine, 2025-03-24
Topic: Risk, prevention and care in population studies
Plain-language summary
This cohort study examines the use of cholinesterase inhibitors and memantine among older adults with dementia after admission into hospice care despite the medications’ limited clinical benefit following enrollment into hospice.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study. This cohort study examines continued use of cholinesterase inhibitors and memantine in older adults with dementia after hospice admission. It notes these medications have limited clinical benefit following enrollment into hospice.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Hunt, L. J., Gan, S., Boscardin, W. J., Harrison, K. L., Growdon, M. E., Muench, U., et al. (2025). Continued Use of Cholinesterase Inhibitors and Memantine in Hospice. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2024.8579
Vancouver
Hunt LJ, Gan S, Boscardin WJ, Harrison KL, Growdon ME, Muench U, et al. Continued Use of Cholinesterase Inhibitors and Memantine in Hospice. JAMA Internal Medicine. 2025. doi:10.1001/jamainternmed.2024.8579. PMID: 40126467.
BibTeX
@article{hunt2025-40126467,
author = {Hunt, Lauren J. and Gan, Siqi and Boscardin, W. John and Harrison, Krista Lyn and Growdon, Matthew E. and Muench, Ulrike and Gerlach, Lauren B. and Smith, Alexander Kingsbury and others},
title = {{Continued Use of Cholinesterase Inhibitors and Memantine in Hospice}},
journal = {JAMA Internal Medicine},
year = {2025},
doi = {10.1001/jamainternmed.2024.8579},
pmid = {40126467},
url = {https://doi.org/10.1001/jamainternmed.2024.8579}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- This cohort study examines the use of cholinesterase inhibitors and memantine among older adults with dementia after admission into hospice care despite the medications’ limited clinical benefit following enrollment into hospice.
Why it matters
This cohort study examines continued use of cholinesterase inhibitors and memantine in older adults with dementia after hospice admission. It notes these medications have limited clinical benefit following enrollment into hospice.
Study details
- Study designcohort study
- Evidence strengthModerate
How this study scored 51/100
Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA Internal Medicine) |
| Journal's citation record | 3 / 4 | JAMA Internal Medicine: journal h-index 258 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 2 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 1.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Michael Alan Steinman: h-index 59 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Michigan: institution h-index 2,240 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40126467) |
| Free to read | 2 / 2 | Free to read |
| Total | 51 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/jamainternmed.2024.8579
- PubMed: 40126467
- Original source →
- Free full text: PubMed Central →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in End-of-life care from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.